IBM's Watson business unit and the New York Genome Center will test a cognitive computing prototype aimed at allowing oncologists to better tailor cancer care.
The collaboration, one of many IBM is planning to widen cognitive computing's footprint, will be the first Watson implementation for genomic research.
Under the partnership:
- The two groups will conduct a joint research study to develop care for glioblastoma, an aggressive brain cancer.
- Examine DNA-based treatment options by using Watson to correlate data from genome sequencing to journals, studies and records.
- Identify patterns in genome sequencing and medical data.
- Refine Watson's algorithms based on the New York Genome Center's data.
Ultimately, IBM wants to use the Watson prototype for a clinical study by the New York Genome Center. The software and analytics tools have been under development for the past decade at IBM Research's Computational Biology Center.
The New York Genome Center specializes in experimental design, genome sequencing, bioinformatics and the computing and data storage infrastructure to crunch the data.